For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 1,376,861 | 702,601.5* | 922,857 | 1,317,980 |
| General and administrative | 1,715,639 | 1,761,852.5* | 1,020,154 | 1,143,249 |
| Total operating expenses | 3,092,500 | 2,464,454 | 1,943,011 | 2,461,229 |
| Loss from operations | -3,092,500 | -2,464,454* | -1,943,011 | -2,461,229 |
| Change in fair value of warrant liability | - | -1,175.5* | -611 | -44 |
| Other income (expense), net | 83,449 | 76,966.5* | 35,224 | 16,803 |
| Total other income (expense), net | 83,449 | 78,142* | 35,835 | 16,847 |
| Net loss | -3,009,051 | -2,386,312* | -1,907,176 | -2,444,382 |
| Deemed dividends | 5,681,616 | -2,975,764* | 2,769,742 | 3,181,786 |
| Net gain attributable to common stockholders | -8,690,667 | 589,452 | -4,676,918 | -5,626,168 |
| Basic EPS | -2.71 | 0.95 | -1.77 | -7.01 |
| Diluted EPS | -2.71 | 0.95 | -1.77 | -7.01 |
| Basic Average Shares | 3,207,720 | 620,785* | 2,644,733 | 802,670 |
| Diluted Average Shares | 3,207,720 | 620,785* | 2,644,733 | 802,670 |
REVELATION BIOSCIENCES, INC. (REVBW)
REVELATION BIOSCIENCES, INC. (REVBW)